This study enrolled 108 participants with SOD1-ALS, who were randomly assigned in a 2:1 ratio to receive either eight infusions of 100 mg tofersen or a placebo over 24 weeks. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.